Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
Authors
Keywords
-
Journal
DRUGS
Volume 81, Issue 16, Pages 1881-1896
Publisher
Springer Science and Business Media LLC
Online
2021-10-01
DOI
10.1007/s40265-021-01601-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
- (2020) Edmond-Jean Bernard et al. DIGESTIVE DISEASES AND SCIENCES
- Sustainability of costs of novel biologicals: Are we all heading for bankruptcy?
- (2020) Robert Likic BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
- (2020) Liese Barbier et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Importance of Countering Biosimilar Disparagement and Misinformation
- (2020) Hillel P. Cohen et al. BIODRUGS
- The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence
- (2020) Brian G. Feagan et al. ADVANCES IN THERAPY
- Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
- (2020) Daniel F. Alvarez et al. BIODRUGS
- Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial
- (2020) Marie-Christine Bielsky et al. DRUG DISCOVERY TODAY
- Future perspectives of therapeutic monoclonal antibodies
- (2019) Kanta Tsumoto et al. Immunotherapy
- Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States
- (2019) A. Teeple et al. CURRENT MEDICAL RESEARCH AND OPINION
- Are we ready to close the discussion on the interchangeability of biosimilars?
- (2019) Hans C. Ebbers et al. DRUG DISCOVERY TODAY
- Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative study
- (2019) Hanna M Tolonen et al. BMJ Open
- Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
- (2018) Ross A. McKinnon et al. BIODRUGS
- Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching
- (2018) Paul Declerck et al. CLINICAL THERAPEUTICS
- Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
- (2018) Hillel P. Cohen et al. DRUGS
- Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges
- (2018) Corrado Blandizzi et al. PHARMACOLOGICAL RESEARCH
- Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
- (2018) Meghna Jani et al. RHEUMATOLOGY
- Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
- (2018) Syed Numan et al. ADVANCES IN THERAPY
- Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
- (2018) Brian G. Feagan et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Comparative immunogenicity assessment of biosimilars
- (2018) Thomas Schreitmüller et al. Future Oncology
- Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland
- (2017) Joan O'Callaghan et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
- (2017) Robert Moots et al. Current Rheumatology Reports
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
- (2016) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
- (2016) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- The design of clinical trials to support the switching and alternation of biosimilars
- (2016) Freddy Faccin et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Clinical considerations for biosimilar antibodies
- (2013) Håkan Mellstedt EJC SUPPLEMENTS
- Biosimilar monoclonal antibodies: a science-based regulatory challenge
- (2013) Paul J Declerck EXPERT OPINION ON BIOLOGICAL THERAPY
- The economic pressures for biosimilar drug use in cancer medicine
- (2012) Paul Cornes Targeted Oncology
- Vaccines and biosimilarity: a solution or a problem?
- (2009) Michael J Corbel et al. Expert Review of Vaccines
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now